Nirav Agrawal

Nirav Agrawal

Auto-generated profile, based on publicly available information

Nirav Agrawal

Division of Gerontology, Geriatrics and Palliative Medicine, University of Maryland, Baltimore, USA

Research Focus & Metrics

Academic Career Length

6Years (2021-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
10 June 2021 in Archives of Disease in Childhood
Verified
Journal Article
Open access
PDF file
RSRajiv Sinha
Rajiv Sinha
NANirav Agrawal
Nirav Agrawal
YXYuanxin Xue
Yuanxin Xue
RCRahul Chanchlani
Rahul Chanchlani
SPSubal Pradhan
Subal Pradhan
SMStephen D Marks
Stephen D Marks
Rituximab is a chimeric monoclonal antibody capable of depleting B cell populations by targeting the CD20 antigen expressed on the cell surface. Its use in oncology, initially in B cell lymphoma and post-transplant lymphoproliferative disorders, predates its current utility in various fields of medicine wherein it has become one of the safest and most effective antibody-based therapies. It was subsequently found to be effective for rheumatological conditions such as rheumatoid arthritis and antineutrophil cytoplasmic antibody-associated vasculitis. Over the past decade, rituximab has generated a lot of interest in nephrology and has become an emerging or accepted therapy for multiple renal conditions, including systemic lupus erythematosus, lupus nephritis, vasculitis, nephrotic syndrome and in different scenarios before and after kidney transplantation. This review outlines its current use in paediatric nephrology practice, focusing on the knowledge required for general paediatricians who may be caring for children prescribed this medication and reviewing them on a shared care basis.

1 January 2022 in Clinical Breast Cancer
Verified
Journal Article
Closed access
PGPanagiota Gianni
Panagiota Gianni
EMEvangelia Matenoglou
Evangelia Matenoglou
GGGeorgios Geropoulos
Georgios Geropoulos
NANirav Agrawal
Nirav Agrawal
HAHarsha Adnani
Harsha Adnani
DGDimitrios Giannis
Dimitrios Giannis

10 March 2021 in Journal of Intensive Care Medicine
Verified
Journal Article
Closed access
PDF file
RRRupesh Raina
Rupesh Raina
NANirav Agrawal
Nirav Agrawal
KKKirsten Kusumi
Kirsten Kusumi
APAvisha Pandey
Avisha Pandey
ATAbhishek Tibrewal
Abhishek Tibrewal
ABAlexander Botsch
Alexander Botsch
Continuous kidney replacement therapy (CKRT) is the primary therapeutic modality utilized in hemodynamically unstable patients with severe acute kidney injury. As the circuit is extracorporeal, it poses an increased risk of blood clotting and circuit loss; frequent circuit losses affect the provider’s ability to provide optimal treatment. The objective of this meta-analysis is to evaluate the safety and efficacy of the extracorporeal anticoagulants in the pediatric CKRT population. We conducted a literature search on PubMed/Medline and Embase for relevant citations. Studies were included if they involved patients under the age of 18 years undergoing CKRT, with the use of anticoagulation (heparin, citrate, or prostacyclin) as a part of therapy. Only English articles were included in the study. Initial search yielded 58 articles and a total of 24 articles were included and reviewed. A meta-analysis was performed focusing on the safety and effectiveness of regional citrate anticoagulation (RCA) vs unfractionated heparin (UFH) anticoagulants in children. RCA had statistically significantly longer circuit life of 50.65 hours vs. UFH of 42.10 hours. Two major adverse effects metabolic alkalosis and electrolyte imbalance seen more commonly in RCA compared to UFH. There was not a significant difference in the risk of systemic bleeding when comparing RCA vs. UFH. RCA is the preferred anticoagulant over UFH due to its significantly longer circuit life, although vigilant circuit monitoring is required due to the increased risk of electrolyte disturbances. Prostacyclin was not included in the meta-analysis due to the lack of data in pediatric patients. Additional studies are needed to strengthen the study results further.

9 August 2026 in Naunyn-Schmiedeberg's Archives of Pharmacology
Verified
Journal Article
Closed access
PDF file
NANirav Agrawal
Nirav Agrawal
ASAkshay Sharma
Akshay Sharma
ACAditya Chandrashekar
Aditya Chandrashekar
MKMuhammad Ali Ibrahim Kazi
Muhammad Ali Ibrahim Kazi
MKMitchell Karpman
Mitchell Karpman
NMNargiz Muganlinskaya
Nargiz Muganlinskaya